Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2020 11:50 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is...
November 02, 2020 09:00 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma

ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahn’s...
June 17, 2020 23:30 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn and Ocuphire Enter into Definitive Merger Agreement

Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates $21.15 Million Investment Committed by...
September 24, 2019 06:50 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn to Explore Strategic Alternatives

ROCKVILLE, Md., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) today announced that it has commenced a process to explore and evaluate strategic alternatives to...
August 07, 2019 06:30 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development

ROCKVILLE, Md., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
May 28, 2019 16:10 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn Announces Move to Nasdaq

ROCKVILLE, Md., May 28, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
May 13, 2019 08:00 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results

ROCKVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
April 16, 2019 08:00 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China

ROCKVILLE, Md. and SUZHOU, China, April 16, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage, biopharmaceutical company focused on oncology, and BioSense...
April 12, 2019 08:00 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn Effects 1-for-12 Reverse Stock Split

ROCKVILLE, MD, April 12, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient...
April 10, 2019 16:07 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn Announces Reverse Stock Split

ROCKVILLE, Md., April 10, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient...